- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Effect of recombinant human interleukin-6 (rhIL-6) and rhIL-3 on hematopoietic regeneration as demonstrated in a nonhuman primate chemotherapy model
-
- EF Winton
- Emory University School of Medicine, Atlanta, GA.
-
- J Srinivasiah
- Emory University School of Medicine, Atlanta, GA.
-
- BK Kim
- Emory University School of Medicine, Atlanta, GA.
-
- CD Hillyer
- Emory University School of Medicine, Atlanta, GA.
-
- EA Strobert
- Emory University School of Medicine, Atlanta, GA.
-
- JL Orkin
- Emory University School of Medicine, Atlanta, GA.
-
- RB Swenson
- Emory University School of Medicine, Atlanta, GA.
-
- HM McClure
- Emory University School of Medicine, Atlanta, GA.
-
- LA Myers
- Emory University School of Medicine, Atlanta, GA.
-
- R Saral
- Emory University School of Medicine, Atlanta, GA.
Search this article
Description
<jats:title>Abstract</jats:title> <jats:p>Using a recently developed hepsulfam-induced pancytopenia model in rhesus macaques, we have studied the effects of recombinant human interleukin-6 (rhIL-6) and rhIL-3 on marrow regeneration. Control animals were given hepsulfam (1.5 g/m2 by a single 30-minute intravenous [i.v.] injection, n = 4), while study animals received hepsulfam followed by rhIL-6, rhIL-3, or a combination of rhIL-6 and rhIL-3 (n = 3 per study group). Each cytokine was administered by once- daily subcutaneous (SC) injection (15 micrograms/kg/d) for 3 weeks beginning the day after chemotherapy (days 2 through 22). Mean platelet counts in control animals were < 100,000/microL on days 15 through 24, with 50% of the counts < 50,000/microL and two of four animals requiring platelet transfusion. In the rhIL-6- and rhIL-6/rhIL-3- treated groups, the nadir mean platelet counts were 164,000 +/- 58,700/microL and 162,300 +/- 23,800/microL, respectively, and occurred on day 15. Platelet counts in the rhIL-3-treated group were similar to those in controls. Mean absolute neutrophil counts (ANCs) < 1,000/microL occurred on days 10 through 29 in control animals, days 8 through 15 in rhIL-6-treated animals, and days 6 through 8 and 13 in rhIL-6/rhIL-3-treated animals. The frequency of ANCs < 500/microL was significantly less in the rhIL-6- and rhIL-6/rhIL-3-treated groups versus control groups (2.7 +/- 0.6 and 2.0 +/- 1.0 vs 7.0 +/- 1.4 occurrences, respectively; P < .05). rhIL-3-treated animals had ANCs similar to those in controls; one animal died with septicemia on day 21. Monkeys receiving rhIL-6 were significantly more anemic during the cytokine administration period; however, the anemia resolved by day 24. Coadministration of rhIL-3 and rhIL-6 partially corrected the anemia. The data indicate that rhIL-6 prevents significant thrombocytopenia and shortens the neutropenic period in this chemotherapy model.</jats:p>
Journal
-
- Blood
-
Blood 84 (1), 65-73, 1994-07-01
American Society of Hematology
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1364233268276735104
-
- ISSN
- 15280020
- 00064971
- http://id.crossref.org/issn/00064971
-
- Data Source
-
- Crossref